Viral infections associated with haemophagocytic syndrome

被引:145
作者
Maakaroun, Nadine Rouphael [1 ]
Moanna, Abeer [2 ]
Jacob, Jesse T. [1 ]
Albrecht, Helmut [3 ]
机构
[1] Emory Univ, Sch Med, Div Infect Dis, Atlanta, GA 30303 USA
[2] Emory Univ, Sch Med, Div Infect Dis, Vet Affairs Med Ctr, Decatur, GA 30033 USA
[3] Univ S Carolina, Div Infect Dis, Columbia, SC 29203 USA
关键词
INFLUENZA-A H5N1; ACTIVE ANTIRETROVIRAL THERAPY; STEM-CELL TRANSPLANTATION; PARVOVIRUS B19 INFECTION; BARR-VIRUS INFECTION; SPONTANEOUS RESOLUTION; TREATMENT STRATEGIES; CLINICAL-FEATURES; KAPOSIS-SARCOMA; MARROW FAILURE;
D O I
10.1002/rmv.638
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Haemophagocytic syndrome (HPS) or haemophagocytic lymphohistiocytosis (HLH) is a rare disease caused by a dysfunction of cytotoxic T cells and NK cells. This T cell/NK cell dysregulation causes an aberrant cytokine release, resulting in proliferation/activation of histiocytes with subsequent haemophagocytosis. Histiocytic infiltration of the reticuloendothelial system results in hepatomegaly, splenomegaly, lymphadenopathy and pancytopenia ultimately leading to multiple organ dysfunctions. Common clinical features include high fevers despite broad spectrum antimicrobials, maculopapular rash, neurological symptoms, coagulopathy and abnormal liver function tests. Haemophagocytic syndrome can be either primary, i.e. due to an underlying genetic defect or secondary, associated with malignancies, autoimmune diseases (also called macrophage activation syndrome) or infections. Infectious triggers are most commonly due to viral infections mainly of the herpes group, with EBV being the most common cause. HPS can be fatal if untreated. Early recognition of the clinical presentation and laboratory abnormalities associated with HPS and prompt initiation of treatment can be life saving. HPS triggered by viral infections generally does not respond to specific antiviral therapy but may be treated with immunosuppressive/immunomodulatory agents and, in refractory cases, with bone marrow transplantation. Copyright (C) 2010 John Wiley & Sons, Ltd.
引用
收藏
页码:93 / 105
页数:13
相关论文
共 149 条
[71]   Treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) in young adults: A report from the HLH Study Center [J].
Imashuku, S ;
Kuriyama, K ;
Sakai, R ;
Nakao, Y ;
Masuda, SI ;
Yasuda, N ;
Kawano, F ;
Yakushijin, K ;
Miyagawa, A ;
Nakao, T ;
Teramura, T ;
Tabata, Y ;
Morimoto, A ;
Hibi, S .
MEDICAL AND PEDIATRIC ONCOLOGY, 2003, 41 (02) :103-109
[72]  
Imashuku S, 1999, BLOOD, V93, P1869
[73]   SOLUBLE INTERLEUKIN-9 RECEPTOR - A USEFUL PROGNOSTIC FACTOR FOR PATIENTS WITH HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS [J].
IMASHUKU, S ;
HIBI, S ;
SAKO, M ;
ISHIDA, Y ;
MUGISHIMA, H ;
CHEN, JM ;
TSUNEMATSU, Y .
BLOOD, 1995, 86 (12) :4706-4707
[74]  
Imashuku S, 1997, INT J HEMATOL, V66, P135
[75]  
Ishii E, 1998, MED PEDIATR ONCOL, V30, P276, DOI 10.1002/(SICI)1096-911X(199805)30:5<276::AID-MPO3>3.3.CO
[76]  
2-7
[77]   Nationwide survey of hemophagocytic lymphohistiocytosis in Japan [J].
Ishii, Eiichi ;
Ohga, Shouichi ;
Imashuku, Shinsaku ;
Yasukawa, Masaki ;
Tsuda, Hiroyuki ;
Miura, Ikuo ;
Yamamoto, Ken ;
Horiuchi, Hisanori ;
Takada, Kenzo ;
Ohshima, Koichi ;
Nakamura, Shigeo ;
Kinukawa, Naoko ;
Oshimi, Kazuo ;
Kawa, Keisei .
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2007, 86 (01) :58-65
[78]   Infection- and malignancy-associated hemophagocytic syndromes - Secondary hemophagocytic lymphohistiocytosis [J].
Janka, G ;
Imashuku, S ;
Elinder, G ;
Schneider, M ;
Henter, JI .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1998, 12 (02) :435-+
[79]   FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS [J].
JANKA, GE .
EUROPEAN JOURNAL OF PEDIATRICS, 1983, 140 (03) :221-230
[80]   Immunosuppressive therapy with antithymocyte globulin and cyclosporine for prolonged marrow failure after hemophagocytic syndrome [J].
Kaito, K ;
Otsubo, H ;
Takei, Y ;
Usui, N ;
Kobayashi, M .
ANNALS OF HEMATOLOGY, 2003, 82 (11) :699-701